Atlanta Capital Management Co. L L C Sells 301,581 Shares of BIO-TECHNE Corp (TECH)

Atlanta Capital Management Co. L L C reduced its holdings in BIO-TECHNE Corp (NASDAQ:TECH) by 15.8% in the third quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,602,498 shares of the biotechnology company’s stock after selling 301,581 shares during the period. BIO-TECHNE makes up 1.5% of Atlanta Capital Management Co. L L C’s portfolio, making the stock its 23rd largest holding. Atlanta Capital Management Co. L L C’s holdings in BIO-TECHNE were worth $327,086,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. BlackRock Inc. grew its stake in shares of BIO-TECHNE by 2.5% in the 2nd quarter. BlackRock Inc. now owns 3,776,455 shares of the biotechnology company’s stock worth $558,726,000 after buying an additional 91,519 shares in the last quarter. Schroder Investment Management Group grew its stake in shares of BIO-TECHNE by 975.1% in the 2nd quarter. Schroder Investment Management Group now owns 2,211,502 shares of the biotechnology company’s stock worth $85,499,000 after buying an additional 2,005,804 shares in the last quarter. Janus Henderson Group PLC grew its stake in shares of BIO-TECHNE by 5.8% in the 2nd quarter. Janus Henderson Group PLC now owns 1,393,027 shares of the biotechnology company’s stock worth $206,098,000 after buying an additional 76,538 shares in the last quarter. Massachusetts Financial Services Co. MA grew its stake in shares of BIO-TECHNE by 13.4% in the 3rd quarter. Massachusetts Financial Services Co. MA now owns 677,968 shares of the biotechnology company’s stock worth $138,381,000 after buying an additional 79,963 shares in the last quarter. Finally, First Trust Advisors LP grew its stake in shares of BIO-TECHNE by 41.1% in the 3rd quarter. First Trust Advisors LP now owns 672,964 shares of the biotechnology company’s stock worth $137,359,000 after buying an additional 195,950 shares in the last quarter. 92.37% of the stock is owned by institutional investors and hedge funds.

TECH stock opened at $159.48 on Monday. BIO-TECHNE Corp has a 12 month low of $125.84 and a 12 month high of $206.04. The company has a debt-to-equity ratio of 0.49, a current ratio of 4.59 and a quick ratio of 3.50. The stock has a market cap of $6.02 billion, a P/E ratio of 39.18, a PEG ratio of 2.81 and a beta of 1.04.

BIO-TECHNE (NASDAQ:TECH) last released its quarterly earnings results on Tuesday, October 30th. The biotechnology company reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. BIO-TECHNE had a net margin of 19.19% and a return on equity of 14.09%. The firm had revenue of $163.00 million during the quarter, compared to analysts’ expectations of $162.34 million. During the same period in the previous year, the company earned $0.90 EPS. The firm’s revenue for the quarter was up 12.7% compared to the same quarter last year. As a group, research analysts expect that BIO-TECHNE Corp will post 3.79 earnings per share for the current year.

The company also recently declared a quarterly dividend, which was paid on Friday, November 23rd. Investors of record on Friday, November 9th were paid a dividend of $0.32 per share. The ex-dividend date of this dividend was Thursday, November 8th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.80%. BIO-TECHNE’s dividend payout ratio is presently 31.45%.

A number of equities analysts have commented on the stock. Zacks Investment Research cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating in a research note on Tuesday, November 6th. Citigroup lifted their price objective on shares of BIO-TECHNE from $160.00 to $205.00 and gave the stock a “buy” rating in a research note on Thursday, August 9th. BidaskClub cut shares of BIO-TECHNE from a “strong-buy” rating to a “buy” rating in a research note on Thursday, October 4th. Leerink Swann set a $190.00 price objective on shares of BIO-TECHNE and gave the stock an “outperform” rating in a research note on Wednesday, August 8th. Finally, Craig Hallum cut shares of BIO-TECHNE from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $215.00 to $154.00 in a research note on Wednesday, October 31st. Four analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. BIO-TECHNE has an average rating of “Buy” and an average target price of $184.13.

TRADEMARK VIOLATION WARNING: This news story was first posted by WKRB News and is the property of of WKRB News. If you are viewing this news story on another site, it was copied illegally and reposted in violation of international copyright & trademark law. The correct version of this news story can be read at https://www.wkrb13.com/2018/11/26/atlanta-capital-management-co-l-l-c-sells-301581-shares-of-bio-techne-corp-tech.html.

BIO-TECHNE Company Profile

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells biotechnology reagents, instruments, and clinical diagnostic controls worldwide. It operates in three segments: Biotechnology, Protein Platforms, and Diagnostics. The Biotechnology segment offers specialized proteins, such as cytokines and growth factors, immunoassays, antibodies, and related reagents to the biotechnology research community; and in situ hybridization, media, and other cell culture products and reagents.

Featured Article: How do candlesticks reflect price movement?

Want to see what other hedge funds are holding TECH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BIO-TECHNE Corp (NASDAQ:TECH).

Institutional Ownership by Quarter for BIO-TECHNE (NASDAQ:TECH)

Receive News & Ratings for BIO-TECHNE Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BIO-TECHNE and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply